SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced that it has completed a 26-week transgenic mouse carcinogenicity study of doxepin, the active pharmaceutical ingredient in its product candidate SILENOR™. Based on the results of this study and a review of such results with its consultant toxicologists, Somaxon intends to proceed with the submission of a New Drug Application for SILENOR™, which is now estimated to occur by mid-February 2008.
